BMS-754807

Catalog No.S1124

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Cited by 5 Publications

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481

Mol Cell Biol, 2015, 35(7):1182-96

PubMed:

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333

PLoS One, 2015, 10(5):e0126867

PubMed: 25962155

1 Customer Review

Clin Cancer Res 2013 19(11), 2984-94. BMS-754807 purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Features

Muti-inhibitor of the IGR-1R/IR family.

Targets

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	View More
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	View More

In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). ^[1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. ^[2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	NYDvUXBGU2mwYYPlJIF{e2G7			NUPhO5p5cW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDJS2YuOVJiKFnDOVAhRSBzM37NLUBidmRidHjlJIRwf26\|dILlZY0hfGG{Z3X0d{BCc3RiKFnDOVAhRSB{Mn7NLUBidmRiTVHQT{ApUUN3MDC9JFE{dk1r	MoHMNVk4PzhyMkS=
IGF-Sal	NWnMcpo2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=			NIPMTJJKSzVyPUegcm0>	M2ixcVE6Pzd6MEK0
CCRF-CEM (ALL)	MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1nW[J42KM7:TR?=	NGfSS5ZFVVOR	NF\KOXVKSzVyPUGuNlM6KM7:TR?=	NHuyN24yQTl7NkK3Ni=>
PC3	MoqwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGPnfVh,PSEQvF2=	M2TEW2ROW09?	Mmj1TWM2OD1yLkm2OUDPxE1?	NHu5SG8yQTl7NkK3Ni=>
JD	MoTRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2\DfJ42KM7:TR?=	M{fo[2ROW09?	NHXGclBKSzVyPUCuN\|kyKM7:TR?=	M1vRS\|E6QTl4Mkey
DU145	MkjiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MofiglUh\|ryP	M17oOGROW09?	NVfLcJpSUUN3ME2xMlQ3PSEQvF2=	M3vISFE6QTl4Mkey
KAG	NFLnUGFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEfjZ4p,PSEQvF2=	NE\MXIZFVVOR	MlLvTWM2OD1zLk[2OUDPxE1?	M{[0cFE6QTl4Mkey
K-562 (CML)	M4n1S2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYP+OUDPxE1?	MmW3SG1UVw>?	Mlz1TWM2OD1{LkOwNkDPxE1?	MmLsNVk6QTZ{N{K=
B6-P210 (Murine ALL)	Mn;IS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2r4Tp42KM7:TR?=	NIGyOVJFVVOR	M3nBcmlEPTB;MT6yPVMh\|ryP	MmH6NVk6QTZ{N{K=
LN CAP-FGC	NVO2OYFnT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGTmS5N,PSEQvF2=	M4L1PWROW09?	M{SyOmlEPTB;MT60N\|Qh\|ryP	NU\BfmJFOTl7OU[yO\|I>
VW	NGTmT\|RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVLC[nJThjVizszN	NGK5Z3VFVVOR	NXT3PJduUUN3ME2wMlAyQSEQvF2=	MojpNVk6QTZ{N{K=
MV411 (B Myelomonocytic)	NIXZb2JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVvjb4ZGhjVizszN	M2XSTmROW09?	M{\PZ2lEPTB;MD6zN{DPxE1?	NV\y[lRCOTl7OU[yO\|I>
MDA-PCa-2b	M2S1[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnXEglUh\|ryP	M2PjW2ROW09?	M36xR2lEPTB;MD6wPVgh\|ryP	M1;HOVE6QTl4Mkey
LG	NIWzbW1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYnJOGlYhjVizszN	M4jL[2ROW09?	NHvK[FRKSzVyPUCuNFM5KM7:TR?=	NEHkTVkyQTl7NkK3Ni=>
RS411 (B cell precursor-ALL)	NE\PSpNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1\RcJ42KM7:TR?=	MXLEUXNQ	M3yw[GlEPTB;MD6xNFIh\|ryP	NHrHNXMyQTl7NkK3Ni=>
22-r-1	NYH6OXRRT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFH6eol,PSEQvF2=	MkiySG1UVw>?	M4DEVWlEPTB;MD6xO\|Uh\|ryP	M2[2b\|E6QTl4Mkey
5838	NXvEc\|A3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUjYUodrhjVizszN	NWT1PIF6TE2VTx?=	NV3UXpN5UUN3ME2wMlA{PCEQvF2=	MXixPVk6PjJ5Mh?=
P388 (Murine)	NYnkXmxXT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVT+OUDPxE1?	MlnvSG1UVw>?	NGrYdJNKSzVyPUSuNlch\|ryP	NYLsWYdDOTl7OU[yO\|I>
A2780/S	MnPLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXn+OUDPxE1?	MVvEUXNQ	NFzWR4pKSzVyPUCuNVIzKM7:TR?=	NX;3WopkOTl7OU[yO\|I>
RDES	NUOxWmNxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M33PWp42KM7:TR?=	MWjEUXNQ	MkPxTWM2OD1yLkCxNkDPxE1?	NISzfIUyQTl7NkK3Ni=>
B6-T315I (Murine B-ALL)	NXHBZnNJT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NH63fmR,PSEQvF2=	MlP2SG1UVw>?	NYfEZ3dnUUN3ME2yMlg{KM7:TR?=	M3T0bFE6QTl4Mkey
TOV 112D	MnzwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M13nXJ42KM7:TR?=	NEe1U\|NFVVOR	NWLYXFUzUUN3ME2yMlE1PiEQvF2=	MnmyNVk6QTZ{N{K=
TC32	NUKz[HlPT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXz+OUDPxE1?	NELXcWZFVVOR	NFizZ5NKSzVyPUCuNFA5KM7:TR?=	NYfic4FtOTl7OU[yO\|I>
HL60 (acute myelocytic)	MkPBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoD2glUh\|ryP	MVfEUXNQ	MmGyTWM2OD1yLkGyJO69VQ>?	NHfTbnYyQTl7NkK3Ni=>
TOV 21G	NVe0eGFsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkLxglUh\|ryP	NWL2bHpnTE2VTx?=	Mn7iTWM2OD12LkK3PUDPxE1?	MWexPVk6PjJ5Mh?=
TC71	NYHv[ZpsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkPiglUh\|ryP	NEjJb45FVVOR	MoTsTWM2OD1yLkCxOEDPxE1?	M4TqXFE6QTl4Mkey
HPN-ALL (T-cell)	MlvFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUP+OUDPxE1?	M{e2eGROW09?	NHHKdFRKSzVyPUCuOVIh\|ryP	MWKxPVk6PjJ5Mh?=
A2780R	M4TWdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVH+OUDPxE1?	NXSzVlYzTE2VTx?=	MWfJR\|UxRTFwNU[0JO69VQ>?	NIPIPZcyQTl7NkK3Ni=>
Rh1	NV3wTYVNT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWiwWYxthjVizszN	NIjqcIxFVVOR	NVmxcWt{UUN3ME2wMlAzPyEQvF2=	NX7pW41TOTl7OU[yO\|I>
Kasumi-1 (acute myeloid)	NF2zXI9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFvZc41,PSEQvF2=	M2Pt[mROW09?	MXzJR\|UxRTBwMU[g{txO	MWexPVk6PjJ5Mh?=
sk-ov-3	NUfobGh3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MoDTglUh\|ryP	MV3EUXNQ	NUXnSYJ3UUN3ME21MlEh\|ryP	MmLGNVk6QTZ{N{K=
ME	M3nW[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NIC0W3l,PSEQvF2=	NX;2ZnNzTE2VTx?=	MlrCTWM2OD1yLkCxOUDPxE1?	NGr0ZZoyQTl7NkK3Ni=>
L1210 (Murine lymphocytic)	Mmj1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYr+OUDPxE1?	M3PMSmROW09?	MlHyTWM2OD1{LkO5JO69VQ>?	NWf2RXI3OTl7OU[yO\|I>
sw-626	M{XsVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVT+OUDPxE1?	M2XBRmROW09?	MoLTTWM2OD1{LkOwOkDPxE1?	M2HUd\|E6QTl4Mkey
CTR	M3fEOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NF30enR,PSEQvF2=	NHizT2hFVVOR	MW\JR\|UxRTBwMkWzJO69VQ>?	NHfRWYIyQTl7NkK3Ni=>
ML2 (Myelomonocytic)	MljRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWL+OUDPxE1?	MUXEUXNQ	NGHoe3JKSzVyPUCuNFkh\|ryP	NVnabI9iOTl7OU[yO\|I>
ovcar-3	MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MV3+OUDPxE1?	MoHISG1UVw>?	NHvOT3pKSzVyPUWg{txO	NX;sUHpLOTl7OU[yO\|I>
Rh36	NILVfoZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MkXyglUh\|ryP	Mnj2SG1UVw>?	NV;INY5yUUN3ME2xMlQ{OiEQvF2=	MVqxPVk6PjJ5Mh?=
MOLM-13 (acute myeloid)	NEnRNHFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MonzglUh\|ryP	MnTlSG1UVw>?	M4G5[2lEPTB;MD60NkDPxE1?	NIPLPWYyQTl7NkK3Ni=>
ovcar-4	NHnvfG1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1[xVZ42KM7:TR?=	Mnq1SG1UVw>?	NHLT[nVKSzVyPUGg{txO	MnXsNVk6QTZ{N{K=
Rh41	NVnXS2FuT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXj+OUDPxE1?	MnflSG1UVw>?	M{C1TGlEPTB;MD6wNFUh\|ryP	M4r4OVE6QTl4Mkey
Mutz 2 (acute myeloid)	NX\MdlVwT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M124Z542KM7:TR?=	MWHEUXNQ	Ml\1TWM2OD1zLkG1JO69VQ>?	NYDlNWJTOTl7OU[yO\|I>
ovcar-5	MUDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4mx[542KM7:TR?=	M3\H[mROW09?	MlzFTWM2OD1yLkC1JO69VQ>?	Mo\VNVk6QTZ{N{K=
RD1	MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGHWUZd,PSEQvF2=	MYfEUXNQ	M{TMfmlEPTB;MD6wOlgh\|ryP	NUi0ZXNSOTl7OU[yO\|I>
OCI-AML 2 (acute myeloid)	NF7sUYJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlrVglUh\|ryP	NVjMTFBSTE2VTx?=	MWTJR\|UxRTNwM{Og{txO	M3ywZVE6QTl4Mkey
786-O	M4rZSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHvpVIF,PSEQvF2=	MWXEUXNQ	NVzqcpNUUUN3ME2xMlY1PyEQvF2=	NYTwSXM2OTl7OU[yO\|I>
A673	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEnLSpl,PSEQvF2=	NGi4XGZFVVOR	MoPHTWM2OD1yLkSwPEDPxE1?	M4XjcFE6QTl4Mkey
TALL-1 (T-cell)	Mni4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXz+OUDPxE1?	Mk\USG1UVw>?	M37nTGlEPTB;MT6yPEDPxE1?	Ml\KNVk6QTZ{N{K=
151-B	NIDYOopIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3fkXZ42KM7:TR?=	M{jGW2ROW09?	MmXxTWM2OD1{Lk[3JO69VQ>?	NXnHNm1DOTl7OU[yO\|I>
PFSK-1	MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFfBcXh,PSEQvF2=	MlHsSG1UVw>?	NUPHbI9pUUN3ME2wMlE{OiEQvF2=	M{njZVE6QTl4Mkey
THP-1	NWX5RZlLT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXz+OUDPxE1?	M2XxVWROW09?	NITtdIlKSzVyPU[uOVgh\|ryP	MWGxPVk6PjJ5Mh?=
HEK293	M{PqZ2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3nZcJ42KM7:TR?=	MoD0SG1UVw>?	NWXiZ5Z{UUN3ME2wMlkyPSEQvF2=	NVzMXoVOOTl7OU[yO\|I>
DAOY	Ml\TS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX7+OUDPxE1?	MXnEUXNQ	NFHuW3dKSzVyPUGuPVc6KM7:TR?=	MkXJNVk6QTZ{N{K=
SET2	MWDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{jIbp42KM7:TR?=	MUDEUXNQ	NXXpeY9HUUN3ME2wMlI6QCEQvF2=	NXG2dpBROTl7OU[yO\|I>
HTB-46	NX2wRpg4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUXoe2FThjVizszN	NGjwbGFFVVOR	M{PkfmlEPTB;NT6yOUDPxE1?	NVHDPVExOTl7OU[yO\|I>
SK-NAS	M1XjUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NE\GSHh,PSEQvF2=	MY\EUXNQ	M{XLfmlEPTB;MD60PVch\|ryP	NGjsT4kyQTl7NkK3Ni=>
CTLL2	NX\Hd3h1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4DUWp42KM7:TR?=	NW\4VHdQTE2VTx?=	NYfwc3RpUUN3ME6xMlAxKM7:TR?=	NWrISo9iOTl7OU[yO\|I>
HTB-47	MoPRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mn7ZglUh\|ryP	NI\yU2hFVVOR	NHm1eHpKSzVyPUKuNFU3KM7:TR?=	NHXOUGYyQTl7NkK3Ni=>
LAN-1	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4r6Zp42KM7:TR?=	MX\EUXNQ	M37UOmlEPTB;MD6wOEDPxE1?	MWWxPVk6PjJ5Mh?=
ST486	NGDGUJlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGfheJB,PSEQvF2=	M1mxSGROW09?	MX3JR\|UxRTFwMUmg{txO	NFXVeIMyQTl7NkK3Ni=>
HS766T	NHO5R\|JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnfuglUh\|ryP	NXvxTGVsTE2VTx?=	M37lSWlEPTB;Mj6wNFEh\|ryP	NXKyfmtGOTl7OU[yO\|I>
IMR-32	NELjeo9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYf+OUDPxE1?	Ml\5SG1UVw>?	NWf4[FNXUUN3ME2wMlI3OSEQvF2=	MmjFNVk6QTZ{N{K=
Daudi (Burkitt's)	MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXjJendyhjVizszN	M3ThTGROW09?	MXHJR\|UxRTJwNkO3JO69VQ>?	MYOxPVk6PjJ5Mh?=
Aspc-1	M3voXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NIe2fGR,PSEQvF2=	MkHkSG1UVw>?	NH7ybWdKSzVyPUCuN\|c6KM7:TR?=	M3jvclE6QTl4Mkey
SK-NSH	NEf5U3hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUXWbVN3hjVizszN	MojlSG1UVw>?	Mk\0TWM2OD1yLkGzPUDPxE1?	NHzXR2wyQTl7NkK3Ni=>
MEC-1 (Chronic B cell)	M1f6cGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnHQglUh\|ryP	NY\xTnBHTE2VTx?=	M3PjN2lEPTB;Mj62N\|ch\|ryP	NFjLT3gyQTl7NkK3Ni=>
Capan-2	NInrOXVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVT4NWVEhjVizszN	M{TLXWROW09?	M1LifmlEPTB;MT63O\|Qh\|ryP	M{jY[FE6QTl4Mkey
SHSY5Y	NH7iPJBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NIjVNIF,PSEQvF2=	MXHEUXNQ	M2TsRmlEPTB;MD6xNFYh\|ryP	MXSxPVk6PjJ5Mh?=
U937 (Histioocytic)	MlfWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIDZ[JJ,PSEQvF2=	M4LYbWROW09?	NFn3SIJKSzVyPkWuNFAh\|ryP	MlizNVk6QTZ{N{K=
Bxpc-1	NX[0R3FCT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFXTS4l,PSEQvF2=	MWTEUXNQ	MnXsTWM2OD1zLkmyOEDPxE1?	MmLHNVk6QTZ{N{K=
Bxpc-3	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnXCglUh\|ryP	MnLjSG1UVw>?	M1vG[2lEPTB-NT6wNEDPxE1?	NG[x[msyQTl7NkK3Ni=>
HTB-92	Ml;xS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mkn2glUh\|ryP	MV3EUXNQ	MoHVTWM2OD1zLkCyJO69VQ>?	NVPxW2wyOTl7OU[yO\|I>
OCI-LY10 (B-cell)	NYLOS2dET3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Mn3zglUh\|ryP	NVnFOnprTE2VTx?=	NWLITZhKUUN3ME2wMlQ2KM7:TR?=	Mn7rNVk6QTZ{N{K=
PANC-1	NV\4VZJXT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2fmPZ42KM7:TR?=	NVixR2pWTE2VTx?=	NYD5W2R2UUN3ME61MlAxKM7:TR?=	MmW0NVk6QTZ{N{K=
To184.T	NGHXeY1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NE\aPXd,PSEQvF2=	MkXvSG1UVw>?	MlzETWM2OD1yLkS2PUDPxE1?	NVHCNW41OTl7OU[yO\|I>
OCI-LY19 (B-cell)	M3noO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NF7HWZB,PSEQvF2=	MWTEUXNQ	NF\NdmlKSzVyPUCuOEDPxE1?	NEn0RnoyQTl7NkK3Ni=>
PANC-1 BM	NWTtZnN2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4jkUp42KM7:TR?=	MnTDSG1UVw>?	NUjQbHEzUUN3ME61MlAxKM7:TR?=	M2C3TlE6QTl4Mkey
SA-4	M2Pkc2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NGXWbGt,PSEQvF2=	MXvEUXNQ	MWDJR\|UxRTFwM{CxJO69VQ>?	MnHQNVk6QTZ{N{K=
RPMI 8226	MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGrB[XB,PSEQvF2=	MYHEUXNQ	MonxTWM2OD1zLkK5N{DPxE1?	NHvXWoMyQTl7NkK3Ni=>
HPAF-II	MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXjTVXBvhjVizszN	NGfodGRFVVOR	Mn;1TWM2OD1yLk[0OEDPxE1?	MmLoNVk6QTZ{N{K=
SHP-77	MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3zycJ42KM7:TR?=	NF3L[o1FVVOR	NWm1b5ZlUUN3ME2xMlg5QCEQvF2=	MmHuNVk6QTZ{N{K=
U266 B1	NYXHe3FQT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MU\+OUDPxE1?	M3TLZmROW09?	NHrlRXNKSzVyPUGuOlY6KM7:TR?=	MVKxPVk6PjJ5Mh?=
Hs700t	NF74O21Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4rCWp42KM7:TR?=	MoHISG1UVw>?	NFK5e5JKSzVyPUCuNlMyKM7:TR?=	M4LxWlE6QTl4Mkey
NCI-446	Mkm1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3O1O542KM7:TR?=	NULCfJVCTE2VTx?=	MnnBTWM2OD1zLkG1OEDPxE1?	MoLrNVk6QTZ{N{K=
H929	M4Kx[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUW0OlJ4hjVizszN	MUPEUXNQ	M1jn[GlEPTB;MD6wNVQh\|ryP	NGHsbIwyQTl7NkK3Ni=>
PL45	NELaS4lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnmzglUh\|ryP	MoLJSG1UVw>?	NInVNohKSzVyPUKuNlU2KM7:TR?=	MXexPVk6PjJ5Mh?=
NCI-H383	NVO2bmpIT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4WwRZ42KM7:TR?=	M4eyZ2ROW09?	MmT1TWM2OD53LkCwJO69VQ>?	MWixPVk6PjJ5Mh?=
JJN3	MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3r1Rp42KM7:TR?=	MULEUXNQ	MW\JR\|UxRTJwNEOzJO69VQ>?	MYmxPVk6PjJ5Mh?=
SU.86.86	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXzpe5dkhjVizszN	M3TB[mROW09?	NX;HTo1WUUN3ME2yMlY4OiEQvF2=	M3zYfVE6QTl4Mkey
H1299	NFTwfJZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYX+OUDPxE1?	NUTlUo1nTE2VTx?=	NEX6S3RKSzVyPkWuNFAh\|ryP	NIfKR4IyQTl7NkK3Ni=>
MDA-MB-468	M1TKeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVX+OUDPxE1?	M4S4TmROW09?	MlfqTWM2OD1yLkWwOEDPxE1?	M3G0clE6QTl4Mkey
SW1990	MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Ml:yglUh\|ryP	Mn3iSG1UVw>?	M4XpNWlEPTB;MD64NlYh\|ryP	NV7yfYlrOTl7OU[yO\|I>
Calu-6	NFX6SXZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWD+OUDPxE1?	NUTHeot6TE2VTx?=	M1TpU2lEPTB-NT6wNEDPxE1?	M2XXWlE6QTl4Mkey
MDA-MB-231	MoXYS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M{H0NJ42KM7:TR?=	M2f5cmROW09?	MX3JR\|UxRTFwNkS4JO69VQ>?	MXuxPVk6PjJ5Mh?=
SW-684	NWDxXlJXT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3rlZ542KM7:TR?=	MmjNSG1UVw>?	MmXMTWM2OD53LkCwJO69VQ>?	MXOxPVk6PjJ5Mh?=
H209	MmTTS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2PDWJ42KM7:TR?=	MlHqSG1UVw>?	NISxXmVKSzVyPUGuNVk{KM7:TR?=	MnjCNVk6QTZ{N{K=
MDA-MB-231T	NHvMNpVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUj+OUDPxE1?	M3O0UmROW09?	NYfmPIVWUUN3ME61MlAxKM7:TR?=	M4L4Z\|E6QTl4Mkey
HT1080/S	NUPreHV2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4jRSJ42KM7:TR?=	NYGyUYN4TE2VTx?=	M4\NRWlEPTB;MD61N\|Eh\|ryP	MYqxPVk6PjJ5Mh?=
H526 0.044	NGLsTo1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUjmZ29KhjVizszN	NF3UWGdFVVOR	MYHJR\|UxRTBwMES0JO69VQ>?	MV2xPVk6PjJ5Mh?=
DU4475 2.431	MoD4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXnjTJdshjVizszN	MVnEUXNQ	MUTJR\|UxRTJwNEOxJO69VQ>?	NV7H[FZbOTl7OU[yO\|I>
HCT116	NGHINYFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFj5XZF,PSEQvF2=	M2L0OWROW09?	MnuwTWM2OD1yLki1NkDPxE1?	MW[xPVk6PjJ5Mh?=
M109	NXPPXodoT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVmxb2M4hjVizszN	MlPzSG1UVw>?	Mk\3TWM2OD1zLkC1OUDPxE1?	MnXsNVk6QTZ{N{K=
BT549	MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVS2NWhphjVizszN	MV7EUXNQ	MV\JR\|UxRTFwNkS1JO69VQ>?	NHnXVZQyQTl7NkK3Ni=>
HCT116/VM46	MojqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoHWglUh\|ryP	NF7FU3hFVVOR	MWrJR\|UxRTFwN{CyJO69VQ>?	MYKxPVk6PjJ5Mh?=
H460	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlPEglUh\|ryP	NYDqRVlMTE2VTx?=	NXX6THJPUUN3ME2wMlc6PSEQvF2=	MoHJNVk6QTZ{N{K=
MCF-7	NXrzfJBoT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGPZWXl,PSEQvF2=	M2DZSWROW09?	MX\JR\|UxRTBwMEG2JO69VQ>?	NXjmfFFFOTl7OU[yO\|I>
GEO	NHXxS3FIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXP+OUDPxE1?	NY\aOVJyTE2VTx?=	NWPYS\|VLUUN3ME2wMlM2PiEQvF2=	M3Hr[FE6QTl4Mkey
H441 0.646	NGDrfWtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NF7NSnh,PSEQvF2=	NF7zTVZFVVOR	M4nJWWlEPTB;MD62OFYh\|ryP	M2m1OlE6QTl4Mkey
MCF-7-807R	NYfsOWhxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2Pve542KM7:TR?=	NVfuOIVXTE2VTx?=	NF7YNmlKSzVyPUCuOFkh\|ryP	Mln6NVk6QTZ{N{K=
Colo205	NI\zSlRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NIPpRXF,PSEQvF2=	MlTWSG1UVw>?	MkDCTWM2OD1yLkGwOEDPxE1?	NUfC[XdHOTl7OU[yO\|I>
H292	MnPKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXnZco9khjVizszN	MlrzSG1UVw>?	MVLJR\|UxRTBwN{i4JO69VQ>?	Mny5NVk6QTZ{N{K=
BT474 (S)	NEfmWnlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3\ROZ42KM7:TR?=	M4KwV2ROW09?	Ml\STWM2OD1{LkSwN{DPxE1?	NFTjdFkyQTl7NkK3Ni=>
HT-29	MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4\lPJ42KM7:TR?=	NFLlV5lFVVOR	NXuxZ\|hwUUN3ME2yMlExOyEQvF2=	MnzRNVk6QTZ{N{K=
A549	NWrh[o5IT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIX5TpN,PSEQvF2=	NF\jXHRFVVOR	NV\XUIdIUUN3ME2wMlY4PSEQvF2=	MkLJNVk6QTZ{N{K=
BT474-M1	MUDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NV;WOlJXhjVizszN	M1fYR2ROW09?	M3;RNWlEPTB;Mj6zOlUh\|ryP	NWXnN3I6OTl7OU[yO\|I>
SW480	NWnqPGl5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3XWR542KM7:TR?=	NF3PdGdFVVOR	NUSwdW1QUUN3ME61MlAxKM7:TR?=	M2HnR\|E6QTl4Mkey
L2987	M16zVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1;JNJ42KM7:TR?=	NGG4UHpFVVOR	MmfKTWM2OD1yLkS0NkDPxE1?	M{\Tb\|E6QTl4Mkey
AU565	M2\yZ2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVn+OUDPxE1?	M{W1NGROW09?	MY\JR\|UxRTRwOUeg{txO	Ml7jNVk6QTZ{N{K=
SW403	NED6Sm9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Mln5glUh\|ryP	MYrEUXNQ	MVjJR\|UxRTBwMkKg{txO	MWixPVk6PjJ5Mh?=
H1437	MX7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MmO0glUh\|ryP	NIXmXFNFVVOR	MmPkTWM2OD1yLkWyN{DPxE1?	M3HxSlE6QTl4Mkey
BT-20	MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVOzV\|lyhjVizszN	M4XBRWROW09?	MWjJR\|UxRTNwNU[yJO69VQ>?	M2fRR\|E6QTl4Mkey
Colo320HSR	NHHGeYdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVLTd4JThjVizszN	M1m4dGROW09?	NXLQcnZRUUN3ME2wMlAyOSEQvF2=	MkHKNVk6QTZ{N{K=
H2087	M4T3cmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHyydWZ,PSEQvF2=	NWK5NpI4TE2VTx?=	MWjJR\|UxRjFwMECg{txO	MYOxPVk6PjJ5Mh?=
HCC1419	Mn:1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NEPvdlB,PSEQvF2=	MWLEUXNQ	MUDJR\|UxRTJwNUG3JO69VQ>?	MX2xPVk6PjJ5Mh?=
WiDr	MnTBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoLFglUh\|ryP	NGH2RlZFVVOR	MmTETWM2OD1yLkC3OkDPxE1?	MYqxPVk6PjJ5Mh?=
H661 0.573	NUfFU2tyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXv+OUDPxE1?	NVrkRphSTE2VTx?=	M2Tob2lEPTB;MD61O\|Mh\|ryP	NYrmZ3Q6OTl7OU[yO\|I>
HCC-38	MkT1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGLOR\|N,PSEQvF2=	M4LGN2ROW09?	NXjwXmhzUUN3ME61MlAxKM7:TR?=	MnS5NVk6QTZ{N{K=
LS174T	MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MkfjglUh\|ryP	NWj3c5hYTE2VTx?=	NWHWS5I4UUN3ME2wMlU{PSEQvF2=	M4H1TVE6QTl4Mkey
H211	NYj6S\|FXT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NETpOI9,PSEQvF2=	MXnEUXNQ	MkXITWM2OD1yLkezN{DPxE1?	M2DadlE6QTl4Mkey
HCC70	NVTMfFNUT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYeydmF2hjVizszN	M3zMR2ROW09?	M3npNWlEPTB;MT61OUDPxE1?	NULBfW5oOTl7OU[yO\|I>
SW116	MnzxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoTJglUh\|ryP	MYDEUXNQ	NVrjcXMyUUN3ME2wMlA3PyEQvF2=	MW[xPVk6PjJ5Mh?=
H513	NWHlRVYxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYf+OUDPxE1?	NVLhc\|g3TE2VTx?=	NFTGTFZKSzVyPUSuOFQ5KM7:TR?=	NIXnPVMyQTl7NkK3Ni=>
MDA-MB-157	MkfJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NWDlR2tuhjVizszN	NIHlXZZFVVOR	M4W3UGlEPTB;MD6wN\|Yh\|ryP	MWKxPVk6PjJ5Mh?=
H2052	MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXT+OUDPxE1?	M2TtTmROW09?	MmfqTWM2OD1zLkC1JO69VQ>?	M4DSeVE6QTl4Mkey
MDA-MB-415	MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4D4Tp42KM7:TR?=	MlXoSG1UVw>?	MUDJR\|UxRjVwMECg{txO	NX36TY42OTl7OU[yO\|I>
DLD-1	M3XO[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2fVfZ42KM7:TR?=	NEDaWFFFVVOR	MV3JR\|UxRTBwOUC5JO69VQ>?	NX\MT21kOTl7OU[yO\|I>
H2595	M13oc2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MX;+OUDPxE1?	Mn3tSG1UVw>?	NFzUW29KSzVyPUSuOFc2KM7:TR?=	M4D2eVE6QTl4Mkey
MDA-MB-435S	MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MkfoglUh\|ryP	MX\EUXNQ	M3KzU2lEPTB;MT64Olkh\|ryP	MVWxPVk6PjJ5Mh?=
HCT15	MUXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXP+OUDPxE1?	MYHEUXNQ	NV33fXdNUUN3ME6xMlAxKM7:TR?=	M{TkN\|E6QTl4Mkey
SK-Hep1	MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVvxS5BmhjVizszN	NH;q[oZFVVOR	Mlj2TWM2OD1yLkG0OkDPxE1?	M1jjR\|E6QTl4Mkey
MDA-MB-436	M3O3Zmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mln0glUh\|ryP	Mm\XSG1UVw>?	NFm0fW5KSzVyPUWuOVAzKM7:TR?=	M{eyTVE6QTl4Mkey
KM12C	NXm5[Zh1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIP5O\|h,PSEQvF2=	NXGyZ\|hCTE2VTx?=	M3i1c2lEPTB;MD6wOVQh\|ryP	MmXsNVk6QTZ{N{K=
HEPG2	M{K2TGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1TBfp42KM7:TR?=	NFXESXZFVVOR	NYLVbZVZUUN3ME2wMlAzPSEQvF2=	MUCxPVk6PjJ5Mh?=
MDA-MB-453	MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Ml60glUh\|ryP	M3ft[WROW09?	MmnITWM2OD1zLki2PUDPxE1?	Ml;ZNVk6QTZ{N{K=
KM12SM	M1HnR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Ml;BglUh\|ryP	M4TJNWROW09?	NHry[I9KSzVyPUCuNFU6KM7:TR?=	NX;zdY9ROTl7OU[yO\|I>
1483	Mlu5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYjEWVZ5hjVizszN	MV\EUXNQ	NWXpdFZ7UUN3ME2yMlE6KM7:TR?=	MmDlNVk6QTZ{N{K=
Hs578t	M4DUNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NF;GcnZ,PSEQvF2=	MmO4SG1UVw>?	MXfJR\|UxRTFwMki3JO69VQ>?	MkDsNVk6QTZ{N{K=
LS180	MmXIS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWT+OUDPxE1?	MljNSG1UVw>?	MUTJR\|UxRTBwNkm2JO69VQ>?	Mnv1NVk6QTZ{N{K=
FaDu	MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Ml76glUh\|ryP	MYLEUXNQ	NFTiOIxKSzVyPUGuNlch\|ryP	NFPDPWEyQTl7NkK3Ni=>
ZR-75-1	M2L5R2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MV3+OUDPxE1?	MVzEUXNQ	MXrJR\|UxRTJwMEi0JO69VQ>?	M1PZeFE6QTl4Mkey
LS513	NGrYS3JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MojwglUh\|ryP	MWfEUXNQ	M17ldWlEPTB;MD6xN\|Uh\|ryP	Mm[1NVk6QTZ{N{K=
Detroit.562	NFLORpFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1Sydp42KM7:TR?=	NYTSUZFXTE2VTx?=	NIPITIJKSzVyPUGuNVQh\|ryP	M{G1dVE6QTl4Mkey
ZR-75-30	NXvWWplsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NF;KTXl,PSEQvF2=	NF7rVJZFVVOR	Ml;OTWM2OD53LkCwJO69VQ>?	NWi0elBDOTl7OU[yO\|I>
RKO-PM	M4mwcGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NEjaSpN,PSEQvF2=	NF3DXG1FVVOR	MnPHTWM2OD1yLkKzNkDPxE1?	MlrlNVk6QTZ{N{K=
Cal.27	NHO2PWpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2TPZ542KM7:TR?=	MnX4SG1UVw>?	MUXJR\|UxRTJizszN	NWHJTnFsOTl7OU[yO\|I>
KPL4	NYjG[IgyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1\4dZ42KM7:TR?=	NY\hbnliTE2VTx?=	M4T2WGlEPTB;MT6yOVIh\|ryP	M3P4fVE6QTl4Mkey
PKO-RM13	NInTTXJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4\iR542KM7:TR?=	M4LGXGROW09?	NWPXOow4UUN3ME2wMlQzPSEQvF2=	M{PhSFE6QTl4Mkey
HS.53.T	MlnJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXj+OUDPxE1?	NU\4[YZQTE2VTx?=	M1\TeGlEPTB;MD63PUDPxE1?	NV\6NpVxOTl7OU[yO\|I>
EMT6	NUjxPHJbT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVf+OUDPxE1?	NVTn[IVnTE2VTx?=	NGTrSJVKSzVyPUCuPFA3KM7:TR?=	MlrINVk6QTZ{N{K=
SNU-C1	M1yzRWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3rNR542KM7:TR?=	MXHEUXNQ	NHK1bVBKSzVyPUCuNFA4KM7:TR?=	NUH1[4NlOTl7OU[yO\|I>
SQCCY1	M3HDOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoW3glUh\|ryP	M3rKUWROW09?	Mof2TWM2OD1yLke5JO69VQ>?	MUixPVk6PjJ5Mh?=
SW480	MX7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mo\XglUh\|ryP	NFnNRZZFVVOR	NYnhToN2UUN3ME2wMlA{PyEQvF2=	M1XrUVE6QTl4Mkey
SCC9	NGe0OnpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUjrOVNDhjVizszN	NVfBbI9GTE2VTx?=	NITQXpZKSzVyPUCuO\|Uh\|ryP	MVOxPVk6PjJ5Mh?=
SK-LMS-1	M1fJZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NH3FT\|N,PSEQvF2=	MmiySG1UVw>?	MlG1TWM2OD1yLk[4O{DPxE1?	MmmzNVk6QTZ{N{K=
SCC25	M3exTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NGm4Nml,PSEQvF2=	MXXEUXNQ	M1zjOWlEPTB;MD62PEDPxE1?	MoflNVk6QTZ{N{K=
U87	NVnuR3lxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIixOGh,PSEQvF2=	M3rXOWROW09?	NETtdYlKSzVyPUCuPVUh\|ryP	NYnDRmp7OTl7OU[yO\|I>
SCC15	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnrrglUh\|ryP	MX3EUXNQ	NXjHSWNuUUN3ME2wMlY4KM7:TR?=	MUixPVk6PjJ5Mh?=
T98G	M4OwXmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mne0glUh\|ryP	NVPPWWF3TE2VTx?=	M2PzTGlEPTB;MT6yNVgh\|ryP	NFn2VFMyQTl7NkK3Ni=>
SCC4	M2C0dmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Ml3WglUh\|ryP	MmjXSG1UVw>?	MVvJR\|UxRTBwNkOg{txO	MUmxPVk6PjJ5Mh?=
U118	M2XIS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MluwglUh\|ryP	M33M[WROW09?	MlPOTWM2OD1zLk[xPEDPxE1?	M2HJRlE6QTl4Mkey
TU167	Mo\HS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3W3NZ42KM7:TR?=	NX6ySnRvTE2VTx?=	NULBVItvUUN3ME20MlUzKM7:TR?=	MknyNVk6QTZ{N{K=
NCI-H727	MkLDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUD4PWI1hjFy4pEK{txO	NFfLUHJFVVOR	MWfJR\|UxRTR{ODDuUS=>	NI\2eGYzODN6NUe0Oy=>
NCI-H720	NX7ubFlqT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGXDOWV,OTEkgJtOwG0>	MlPvSG1UVw>?	MYHJR\|UxRTJwODFOwG0>	MnjUNlA{QDV5NEe=
NCI-H835	NHzqemVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXf+NVDjiIsQvF2=	M{XVemROW09?	NYTYVop4UUN3ME2xJO69VQ>?	NVvkU29UOjB\|OEW3OFc>
NCI-H727	NX;zPGIyU2mwYYPlJIF{e2G7	MlLqglEx6oDMzszN	NVnXblVxTE2VTx?=	NV;tXHlCcW6qaXLpeJMh[2:wc4TpeJV1cX[nIFnHSlFTKGG3dH;wbI9{eGixconsZZRqd25?	MlzyNlA{QDV5NEe=
RD	NUjDd41CT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MlnNglEx6oDMzszN		NWrBS3AyUUN3ME2xMlEzKML3TR?=	M3zCc\|IyOjl6N{S1
Rh41	M3;LbGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2nyOp4yOOLCit88US=>		NFy2W25KSzVyPUCuNFchyrWP	M2\oSFIyOjl6N{S1
Rh18	Mn7SS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWn+NVDjiIsQvF2=		NXfz[mFGUUN3ME20Mlk3KML3TR?=	NFLX[lEzOTJ7OEe0OS=>
Rh30	MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVvJXVBPhjFy4pEK{txO		NYnQZ2I2UUN3ME2wMlE6KML3TR?=	NWHpeYZ1OjF{OUi3OFU>
BT-12	NWSzRXdjT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1fCSp4yOOLCit88US=>		MX;JR\|UxRTBwN{igxtVO	M1PZcFIyOjl6N{S1
CHLA-266	M4joNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3rPWJ4yOOLCit88US=>		NXPWO4NvUUN3ME2wMlg6KML3TR?=	M3naSFIyOjl6N{S1
TC-71	M1nwSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUnaS2NPhjFy4pEK{txO		MVvJR\|UxRTBwMUGgxtVO	NIrSbHYzOTJ7OEe0OS=>
CHLA-9	NWTVRYtjT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NE[4fJp,OTEkgJtOwG0>		M1zUVWlEPTB;MD6xNkDDvU1?	MkL6NlEzQTh5NEW=
CHLA-10	M3r2emdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWPMR4pNhjFy4pEK{txO		NGjRbHlKSzVyPUCuOlIhyrWP	MonpNlEzQTh5NEW=
CHLA-258	MnK2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4\LfZ4yOOLCit88US=>		M3i1PWlEPTB;MD6yO{DDvU1?	NYDYPJc5OjF{OUi3OFU>
GBM2	Mlm3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M13CWZ4yOOLCit88US=>		NVvF[XJjUUN3ME2xMlQ4KML3TR?=	MUOyNVI6QDd2NR?=
NB-1643	NHnub2dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnW2glEx6oDMzszN		NYnPXJJmUUN3ME2wMlEzKML3TR?=	NI\HUWIzOTJ7OEe0OS=>
NB-EBc1	NV3pfnMxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUj+NVDjiIsQvF2=		MVHJR\|UxRTBwM{WgxtVO	MnrsNlEzQTh5NEW=
CHLA-90	NEXtfnZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1;2U54yOOLCit88US=>		MULJR\|UxRTBwN{egxtVO	MYqyNVI6QDd2NR?=
CHLA-136	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NG\Hd45,OTEkgJtOwG0>		MULJR\|UxRTBwNUKgxtVO	NVzLN5hQOjF{OUi3OFU>
NALM-6	MoXYS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVHVenRphjFy4pEK{txO		Mn\MTWM2OD1yLkS5JOK2VQ>?	MmXWNlEzQTh5NEW=
COG-LL-317	NW\SWmx4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NV6xTll[hjFy4pEK{txO		M1\NVWlEPTB;MT6zPEDDvU1?	NVjEWmF{OjF{OUi3OFU>
RS4;11	NYP4d\|V5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3zHc54yOOLCit88US=>		MXXJR\|UxRTBwM{igxtVO	MnXQNlEzQTh5NEW=
MOLT-4	MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3Ljcp4yOOLCit88US=>		M{GwUWlEPTB;MD61N{DDvU1?	NXG1XmR3OjF{OUi3OFU>
CCRF-CEM	MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mn\DglEx6oDMzszN		NX7IdZVYUUN3ME2xMlE{KML3TR?=	NG\ydlMzOTJ7OEe0OS=>
Kasumi-1	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NX\j[YZ[hjFy4pEK{txO		M3TnSmlEPTB;MT6yJOK2VQ>?	NGn4WIEzOTJ7OEe0OS=>
Karpas-299	M2D2bmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkTQglEx6oDMzszN		M2jHUWlEPTB;MT62OEDDvU1?	MV2yNVI6QDd2NR?=
Ramos-RA1	MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3LqNJ4yOOLCit88US=>		MmnJTWM2OD1zLkOxJOK2VQ>?	M{G1NFIyOjl6N{S1
Rh30	MYjGeY5kfGmxbjDhd5NigQ>?			Mn7KbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w	NWnORlB3OjV7MkWzO\|g>
Rh41	Ml25SpVv[3Srb36gZZN{[Xl?			MlLGbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w	M{GyUFI2QTJ3M{e4
RD	NH3xeIxHfW6ldHnvckBie3OjeR?=			NVPsSHFXcW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u	MoHkNlU6OjV\|N{i=
A549	NIXv[pZMcW6jc3WgZZN{[Xl?	NGr2U\|QxNjYkgJtOwG0>	NETHcXNFVVOR	MofobY5pcWKrdIOgTWdHNUmUL1nSJIFkfGm4YYTpc44>	MkDnNlY6Ojh3N{i=
NCI-H358	MXfLbY5ie2ViYYPzZZk>	NXvKO3ExOC534pEK{txO	MX3EUXNQ	MUjpcohq[mm2czDJS2YuUVJxSWKgZYN1cX[jdHnvci=>	M1S4eFI3QTJ6NUe4
A549	MoniSpVv[3Srb36gZZN{[Xl?	MUOwMlXjiIsQvF2=	MkDGSG1UVw>?	MWrjZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM	MYeyOlkzQDV5OB?=
NCI-H358	NGLwU\|FHfW6ldHnvckBie3OjeR?=	MoHGNE426oDMzszN	M{XxfGROW09?	NWLJemh[[2G3c3XzJIEh[2:wY4XydoVvfCCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgZY5lKEWUSx?=	NF;Ec28zPjl{OEW3PC=>
A549	MWDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVXWV2E4hjFy4pEK{txO	M1zZTmROW09?	M4fa[2lEPTB;MD63OkDPxE1?	M2nre\|I3QTJ6NUe4
NCI-H358	NHrV[mtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVP+NVDjiIsQvF2=	MoHqSG1UVw>?	NWLoO2t4UUN3ME2xMlA6KM7:TR?=	MVeyOlkzQDV5OB?=
A549	MnfvRZBweHSxc3nzJIF{e2G7	NF;FWGgxNjYkgJtOwG0>	MYHEUXNQ	M4TKWolv\HWlZYOgRZBweHSxc3nz	NV;STJF7OjZ7Mki1O\|g>
NCI-H358	M{HnNmFxd3C2b4Ppd{Bie3OjeR?=	MXKwMlXjiIsQvF2=	MV\EUXNQ	NXLQOWZScW6mdXPld{BCeG:ydH;zbZM>	M{X0eVI3QTJ6NUe4
A549	NEe3eHhHfW6ldHnvckBie3OjeR?=	NUXj[olkOC534pEK{txO	NVzpd4dmTE2VTx?=	M1Pke5Jm\HWlZYOge492dmRiY3zvd5Vz\Q>?	MW[yOlkzQDV5OB?=
NCI-H358	NX\xZmNpTnWwY4Tpc44h[XO\|YYm=	NFS3cYwxNjYkgJtOwG0>	NF;FSHdFVVOR	NYHYb3NvemWmdXPld{B4d3WwZDDjcI9{fXKn	NIT4VHozPjl{OEW3PC=>

... Click to View More Cell Line Experimental Data

In vivo

BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. ^[1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. ^[2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. ^[3]

Protocol

Kinase Assay:^[1]	+ Expand Kinase inhibition assays: The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to K_m ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:^[1]	+ Expand Cell lines: IGF-1R-Sal, RH41 and Geo cell lines Concentrations: 365 nM Incubation Time: 72 hours Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of ³H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol) Dosages: 150 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BMS-754807 SDF

Molecular Weight	461.49
Formula	C₂₃H₂₄FN₉O
CAS No.	1001350-96-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01525823	Completed	Healthy Volunteers	Bristol-Myers Squibb	February 2012	Phase 1
NCT01225172	Completed	Breast Cancer	Bristol-Myers Squibb\|Mayo Clinic	December 2010	Phase 2
NCT00908024	Terminated	Colorectal Cancer\|Head and Neck Cancer\|Neoplasm Metastasis	Bristol-Myers Squibb	October 2009	Phase 1\|Phase 2
NCT00898716	Completed	Neoplasms	Bristol-Myers Squibb	September 2009	Phase 1
NCT00788333	Completed	Breast Cancer	Bristol-Myers Squibb	July 2009	Phase 1\|Phase 2
NCT00793897	Completed	Advanced Solid Tumors\|Metastatic Solid Tumors	Bristol-Myers Squibb	April 2009	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Selective IGF-1R Inhibitor

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
IGF-1R Inhibitor in Clinical Trial

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
Classic IGF-1R Inhibitor

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

Related IGF-1R Products4

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 5 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 5 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)